SCORAD

SCORAD (SCORing Atopic Dermatitis) was developed by the European Task Force on Atopic Dermatitis in 1993. It is a clinician tool for measuring how widespread and how severe Atopic Dermatitis is, and dermatologists use it before and after treatment to judge whether the treatment worked (DermNet). The formula is A/5 + 7B/2 + C. A is the extent, the percentage of body surface affected (rule of nines, max 100). B is the intensity of six signs, each scored 0–3 on a representative patch: redness, swelling, oozing/crusting, scratch marks, Lichenification and dryness. Dryness is scored on uninflamed skin, and B has a maximum of 18. C is two subjective 0–10 visual analogue scales covering itch and sleeplessness, rated by the patient or a relative (max 20). The total runs from 0 to 103. The version without C is called objective SCORAD (oSCORAD) and runs from 0 to 83.

SCORAD [defines] Atopic Dermatitis SCORAD [relates] Lichenification

Who fills it in. A clinician scores A and B. For toddlers, the C items (itch and sleep loss) are rated by the parent, so SCORAD is a hybrid of clinician and parent input. It is the most common outcome in European paediatric eczema trials, and many trials in this vault report it (Bathing Frequency, Coconut Oil, Ceramides, Elimination Diets). Because the C items count itch and sleep, a toddler with clear skin can still score above 0 if dryness, itch or poor sleep is present (Chopra 2017).

SCORAD [relates] Itch-Scratch Cycle SCORAD [relates] Sleep Disturbance in Eczema

Severity bands. The oldest bands come from the European Task Force consensus report (Kunz et al., Dermatology 1997). That paper was an inter-observer study of 19 patients (14 children, 5 adults) scored by 23 physicians. It proposed grading severity “according to objective criteria in three groups” for trial inclusion (PubMed abstract). The three groups are for objective SCORAD: <15 mild, 15–40 moderate, >40 severe. They were set by author consensus without formal testing. The widely quoted total-SCORAD bands, <25 mild, 25–50 moderate, >50 severe, came later by adding 10 points to the oSCORAD cut-offs, also without formal testing (Healio clinical guidance, citing Kunz 1997 and Chopra 2017). So “<25 / 25–50 / >50” is often credited to Kunz, but it is an extrapolation from his oSCORAD bands, not a band he tested. Chopra et al. (BJD 2017) anchored SCORAD to a clinician’s global assessment in adolescents and adults and proposed 0–9.9 clear, 10–28.9 mild, 29–48.9 moderate, 49–103 severe. For oSCORAD they proposed 0–7.9 clear, 8–23.9 mild, 24–37.9 moderate and ≥38 severe. A 2024 analysis of dupilumab-trial data in adults (Wollenberg et al., BJD abstract) re-fitted both schemes into five bands. None of these bands was derived in 1–4-year-olds, so they should be applied to a toddler with caution.

Conflict: [Kunz et al., Dermatology, 1997 — consensus, untested] puts the objective-SCORAD bands at <15 / 15–40 / >40; the derived total-SCORAD bands are <25 / 25–50 / >50 (Healio). [Chopra et al., BJD, 2017 — anchor-based] puts total SCORAD at <29 mild, 29–48.9 moderate, ≥49 severe and oSCORAD at <24 / 24–37.9 / ≥38. [Wollenberg et al., BJD abstract, 2024] gives different five-band schemes again. Unresolved — add to open_questions.

Skin of colour. SCORAD scores redness as one of its six intensity signs, and redness is hard to see on brown and black skin. In a London cohort of 137 children scored with SCORAD, black children had a crude odds ratio for severe disease of 0.84 against white children. After adjusting for the erythema score it rose to 5.93 (Ben-Gashir & Hay, BJD 2002). Erythema-led scoring can therefore hide severe eczema in black toddlers. See Eczema in Skin of Colour.

Eczema in Skin of Colour [relates] SCORAD

HOME position. The HOME Initiative reviewed 16 sign-scoring instruments. It found only EASI and objective SCORAD extensively validated, and chose EASI as the single core instrument for clinical signs in trials (Schmitt 2014). SCORAD is therefore no longer the recommended core trial outcome. It is still widely used in clinics and older trials, and a patient-oriented version (PO-SCORAD) was one of the five symptom instruments HOME considered before it settled on POEM.

HOME Initiative [regulates] SCORAD EASI [opposes] SCORAD

Connections

• Atopic Dermatitis — severity measure, source: DermNet SCORAD
• Bathing Frequency — outcome in bathing-frequency RCTs, source: Cardona 2020; Koutroulis 2014
• EASI — HOME-preferred alternative for clinical signs, source: Schmitt 2014
• POEM — parent-reported symptom measure, source: HOME VII 2021
• HOME Initiative — validated SCORAD but chose EASI as core signs instrument, source: Schmitt 2014
• Sleep Disturbance in Eczema — sleeplessness VAS is part of score C, source: DermNet SCORAD
• Itch-Scratch Cycle — itch VAS and scratch marks are scored, source: DermNet SCORAD
• Atopic March — AD severity is the strongest predictor of progression, source: Medicina 2024
• Eczema in Skin of Colour — erythema item under-scores severity in black children, source: Ben-Gashir & Hay 2002
• TREAT Trial — o-SCORAD co-primary outcome, source: Flohr BJD 2023